Corbus Pharmaceuticals Holdings (LTS:0SZI) Cyclically Adjusted PS Ratio: (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SZI Corbus Pharmaceuticals Holdings Inc LTS:0SZI
46 GF Score
Price $9.22
GF Value $1.01
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Corbus Pharmaceuticals Holdings  (LTS:0SZI) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Corbus Pharmaceuticals Holdings Cyclically Adjusted PS Ratio Related Terms


Corbus Pharmaceuticals Holdings Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Cyclically Adjusted PS Ratio Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0SZI vs OKUR, HUMA, TNYA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Cyclically Adjusted PS Ratio falls into.


LTS:0SZI
46GF Score
Corbus Pharmaceuticals Holdings Inc LTS:0SZI
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Corbus Pharmaceuticals Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Corbus Pharmaceuticals Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Corbus Pharmaceuticals Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.307 241.018 0.421
201609 0.509 241.428 0.696
201612 0.254 241.432 0.347
201703 0.837 243.801 1.134
201706 0.209 244.955 0.282
201709 0.476 246.819 0.637
201712 0.000 246.524 0.000
201803 0.506 249.554 0.670
201806 0.448 251.989 0.587
201809 0.572 252.439 0.748
201812 1.010 251.233 1.328
201903 0.917 254.202 1.191
201906 12.739 256.143 16.423
201909 1.202 256.759 1.546
201912 1.194 256.974 1.534
202003 0.763 258.115 0.976
202006 0.116 257.797 0.149
202009 0.451 260.280 0.572
202012 0.226 260.474 0.287
202103 0.167 264.877 0.208
202106 0.035 271.696 0.043
202109 0.023 274.310 0.028
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.000 307.789 0.000
202312 0.000 306.746 0.000
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Corbus Pharmaceuticals Holdings (LTS:0SZI) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of $9.22 is trading 813.3% above its estimated GF Value™ of $1.01. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for LTS:0SZI:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $1.01 vs. price of $9.22 (813.3% above fair value)
  • GF Score™: 46/100 with 1 warning sign

No single metric tells the full story. See the LTS:0SZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
46GF Score

Get the complete analysis for LTS:0SZI

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.22
Price
$1.01
GF Value